| Recruiting | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid NCT06947499 | LG Chem | Phase 2 / Phase 3 |
| Completed | The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine NCT03931239 | Vabiotech | N/A |
| Withdrawn | Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at NCT03128489 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers NCT02853929 | GlaxoSmithKline | Phase 4 |
| Completed | A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a NCT02858440 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 NCT02428491 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 a NCT02096263 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix® NCT01978093 | GlaxoSmithKline | Phase 3 |
| Completed | Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve NCT01878435 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Completed | Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa NCT01983540 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers NCT01577732 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) V NCT01353703 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/H NCT01453998 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib NCT01449812 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/H NCT01358825 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine NCT01309646 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217 NCT01248884 | GlaxoSmithKline | Phase 2 |
| Completed | Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. NCT01214889 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster NCT01171989 | GlaxoSmithKline | Phase 2 |
| Completed | Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Health NCT01000974 | GlaxoSmithKline | Phase 3 |
| Completed | Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants NCT01090453 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy To NCT01106092 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine NCT01086423 | GlaxoSmithKline | Phase 3 |
| Completed | A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy NCT01062477 | Sanofi | Phase 3 |
| Completed | Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) NCT00964028 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Month NCT00970307 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants NCT00871338 | GlaxoSmithKline | Phase 2 |
| Completed | Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hi NCT00891176 | GlaxoSmithKline | Phase 3 |
| Terminated | Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months NCT00871741 | GlaxoSmithKline | Phase 2 |
| Unknown | Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine NCT00877357 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b NCT00808392 | Novartis Vaccines | Phase 3 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants NCT00753649 | GlaxoSmithKline | Phase 4 |
| Completed | Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b NCT00734565 | Novartis Vaccines | Phase 1 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants NCT00831753 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine NCT00617812 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine NCT00674908 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine NCT00627458 | GlaxoSmithKline | Phase 2 |
| Completed | Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants NCT00586612 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix NCT00534833 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. NCT00345683 | GlaxoSmithKline | Phase 3 |
| Completed | Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib NCT00473668 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine NCT00454987 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months NCT00453570 | Sanofi | Phase 3 |
| Unknown | Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease NCT00932269 | Swedish Institute for Infectious Disease Control | — |
| Completed | Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) NCT00441012 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai NCT00401531 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age NCT00376779 | GlaxoSmithKline | Phase 2 |
| Completed | Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccin NCT00359983 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Mont NCT00379977 | GlaxoSmithKline | Phase 3 |
| Completed | Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of NCT00345579 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paedia NCT00362336 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and To NCT00343421 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and NCT00313911 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to NCT00326118 | GlaxoSmithKline | Phase 3 |
| Completed | Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTP NCT00332566 | GlaxoSmithKline | Phase 3 |
| Completed | Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC NCT00322335 | GlaxoSmithKline | Phase 3 |
| Completed | Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Va NCT00327184 | GlaxoSmithKline | Phase 3 |
| Terminated | Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 M NCT00316680 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine NCT00289783 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule NCT00287092 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infan NCT00197275 | GlaxoSmithKline | Phase 3 |
| Completed | Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m NCT00136604 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Sch NCT00316147 | GlaxoSmithKline | Phase 3 |
| Completed | Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjuga NCT00307567 | GlaxoSmithKline | Phase 2 |
| Completed | Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children NCT00228917 | GlaxoSmithKline | Phase 3 |
| Completed | Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines NCT00134719 | GlaxoSmithKline | Phase 2 |
| Completed | Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given Wi NCT00263653 | GlaxoSmithKline | Phase 3 |
| Completed | Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given i NCT00169442 | GlaxoSmithKline | Phase 3 |
| Completed | Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine NCT00258700 | GlaxoSmithKline | Phase 3 |
| Completed | Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Health NCT00325156 | GlaxoSmithKline | Phase 4 |
| Completed | Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects NCT00323050 | GlaxoSmithKline | Phase 3 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinea NCT00831311 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine NCT00129129 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Bi NCT00317161 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B NCT00317187 | GlaxoSmithKline | Phase 3 |
| Completed | Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vacc NCT00290303 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis NCT00317135 | GlaxoSmithKline | Phase 3 |
| Completed | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis NCT00325143 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccinati NCT01457547 | GlaxoSmithKline | Phase 4 |
| Completed | Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines NCT00254917 | Sanofi | Phase 4 |
| Completed | Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanri NCT01061541 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. NCT00317174 | GlaxoSmithKline | Phase 2 |
| Completed | The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine NCT00197782 | Public Health England | Phase 4 |
| Completed | 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococc NCT00129116 | GlaxoSmithKline | Phase 2 |
| Completed | Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccin NCT00127855 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Eliminate Hib Carriage in Rural Alaska Native Villages NCT00153556 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended NCT00662870 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vacc NCT01457560 | GlaxoSmithKline | Phase 3 |